Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

NCT04741490 | Unknown

• 1 other identifier: OBU-FJ-BC-EC-II-003
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This is an investigator-initiated, single-arm, single-center, exploratory clinical study.The study population consisted of patients with R0 resection of esophageal squamous cell carcinoma who had not received radiation therapy.The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with radiotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.About 20 subjects are planned to be enrolled in this study.Drug regimen: Patients with esophageal squamous cell carcinoma received radiotherapy combined with carrilizumab adjuvant therapy for 6 cycles 1-3 months after R0 resection.

Conditions

Esophageal Squamous Cell Carcinomas

Outcome Measures

Primary Outcomes (1)

• 1-year disease-free survival rate (1-year DFS)

  The percentage of subjects who were free of disease recurrence or death from the start of study enrolment to 12 months later.

  up to approximately 1 year

Secondary Outcomes (3)

• Progression-Free Survival (PFS)

  up to approximately 2 year

• Disease-free survival (DFS)

  up to approximately 2 year

• Overall survival (OS)

  up to approximately 3 year

Study Arms (1)

treatment group

EXPERIMENTAL

The adjuvant treatment of radiotherapy combined with carrilizumab lasted for 6 cycles

Drug: Camrelizumab; Radiation: radiotherapy

Interventions

Camrelizumab DRUG

PD-1antibodies，200mg ivgtt Q3W

treatment group

radiotherapy RADIATION

45-55Gy/1.8～2.0Gy

treatment group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 - 75 year，male or female；
• The clinical stages of esophageal squamous cell carcinoma diagnosed by pathology (including histology or cytology) were T1-4AN0M0 and T1-4AN +M0
• Patients who underwent surgical resection and were assessed as R0.However, patients who have received previous radiotherapy should be excluded
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；
• Survival expectation ≥ 3 months;
• The laboratory test value of the patient before medication should meet the following standards:
• Routine blood：WBC≥3.0 × 109/L；ANC≥1.5 × 109/L；PLT≥90 × 109/L；HGB≥9.0 g/dL；
• Liver function：TBIL≤1.5 × ULN，AST≤2.5 × ULN，ALT≤2.5 × ULN（Subjects with liver metastasis，AST≤5× ULN，ALT≤5 × ULN）；
• Renal function：Cr≤1.5 × ULN or CrCl ≥50 mL/min；
• Blood coagulation function：INR≤1.5，APTT≤1.5 ×ULN ；
• Women of childbearing age must have a serum pregnancy study within 2 weeks prior to the first dose and the results are negative. Female subjects of childbearing age and partners who are women of childbearing age must be contraceptive during the study period and within 180 days after the last administration of the study drug;

You may not qualify if:

• Known or suspected history of active autoimmune diseases, autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)
• Have a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency disease, or history of organ transplantation and bone marrow transplantation；
• Interstitial lung disease, drug-induced pneumonia, radiation pneumonitis requiring steroid therapy or active pneumonia with clinical symptoms or severe pulmonary dysfunction；
• There are clinical symptoms or diseases of the heart that are not well controlled, such as: (1) heart failure of NYHA class 2 or higher (2) unstable angina (3) myocardial infarction within 24 weeks (4) clinical need for treatment or Interventional supraventricular or ventricular arrhythmia；
• Have a tendency to hereditary bleeding or coagulopathy. Clinically significant bleeding symptoms or clear bleeding tendency within 3 months prior to enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood++ and above；
• Has not fully recovered from toxicity and/or complications from any intervention prior to initiation of treatment (i.e., ≤ grade 1 or level required at baseline, excluding fatigue or hair loss);
• Allergic reactions to test drugs for this application；
• Pregnant or lactating women；

Sponsors & Collaborators

• Fuzhou General Hospital: lead

Study Sites (1)

Fuzhou General Hospital

Fuzhou, Fujian, 350025, China

RECRUITING

MeSH Terms

Interventions

camrelizumab; Radiotherapy

Intervention Hierarchy (Ancestors)

Therapeutics

Central Study Contacts

Zhichao Fu, Prof

CONTACT

13774562945; fauster1112@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 3, 2021
• First Posted: February 5, 2021
• Study Start: February 1, 2021
• Primary Completion: August 1, 2022
• Study Completion: August 1, 2023
• Last Updated: February 5, 2021

Record last verified: 2021-02

Locations

CN (1)